INNO-235

N/A

Report date: 2025/12/23 17:47:53
NMEFirst In Class

Base Information

Drug NameINNO-235
Drug Alias NameINNO-235INNO235
ClassificationSmall molecules > Molecular Glue
Mechanisms of ActionEukaryotic peptide chain release factor GTP-binding subunit ERF3A degradersCasein kinase I isoform alpha degraders
TargetsEukaryotic peptide chain release factor GTP-binding subunit ERF3ACasein kinase I isoform alpha
Therapy Area/IndicationsBurkitt Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesInnovo Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesInnovo Therapeutics IncShandong First Medical UniversityProvincial Hospital Affiliated To Shandong University
Inactive CompaniesN/A
Active IndicationsBurkitt Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A